Last reviewed · How we verify
Delayed second dose of oral cholera vaccine, Euvichol-Plus
Delayed second dose of oral cholera vaccine, Euvichol-Plus is a Biologic drug developed by Epicentre. It is currently FDA-approved.
Euvichol-Plus, a delayed second dose oral cholera vaccine marketed by Epicentre, holds a position in the global cholera prevention market. A key strength is the protection of its core composition through a patent expiring in 2028. The primary risk is the lack of reported revenue and key trial results, which may impact investor confidence and market adoption.
At a glance
| Generic name | Delayed second dose of oral cholera vaccine, Euvichol-Plus |
|---|---|
| Sponsor | Epicentre |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Delayed second dose of oral cholera vaccine, Euvichol-Plus CI brief — competitive landscape report
- Delayed second dose of oral cholera vaccine, Euvichol-Plus updates RSS · CI watch RSS
- Epicentre portfolio CI